Seong-Keun Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seong-Keun Yoo has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Diego Chowell
Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute New York, New York
23 shared publications - Adam M. Farkas
Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute New York, New York
22 shared publications - Amir Horowitz
Department of Immunology and Immunotherapy, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA
22 shared publications - Andrew Elliott
Caris Life Sciences, Phoenix, USA
22 shared publications - Aparna Ananthanarayanan
Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute New York, New York
22 shared publications - Aparna Chhibber
Bristol Myers Squibb 5 , Princeton, New Jersey
22 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S6 shows RNAscope of IL6 and CXCL9 transcript in UC tumors
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S6 shows RNAscope of IL6 and CXCL9 transcript in UC tumors
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S13 shows CXCL9+-like Macs show superior antigen-specific T-cell activation compared to SPP1+-like Macs
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S13 shows CXCL9+-like Macs show superior antigen-specific T-cell activation compared to SPP1+-like Macs
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S11 shows the enrichment of CLEC5A + TREM1+ Macs in tumor as compared to normal-adjacent tissue
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S11 shows the enrichment of CLEC5A + TREM1+ Macs in tumor as compared to normal-adjacent tissue
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S4 shows plasma IL-6 and CSF-1 are elevated in UC and in ICB non-responders
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S4 shows plasma IL-6 and CSF-1 are elevated in UC and in ICB non-responders
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S16 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S16 shows mIHC of UC tumors corresponding to MARQO analysis
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S16 shows mIHC of UC tumors corresponding to MARQO analysis
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S18 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S18 shows IL-6 signaling selectively limits the differentiation of naĂŻve CD8+ and CD4+ T cells into effector T cells
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S18 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S18 shows IL-6 signaling selectively limits the differentiation of naĂŻve CD8+ and CD4+ T cells into effector T cells
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S2 shows multivariable Cox proportional hazards regression analyses
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S2 shows multivariable Cox proportional hazards regression analyses
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S8 shows the spatial localization of CXCL9+ and SPP1+ Macs relative to tumor vasculature
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S8 shows the spatial localization of CXCL9+ and SPP1+ Macs relative to tumor vasculature
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S12 shows assessment of modeling SPP1+ Macs ex vivo
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S12 shows assessment of modeling SPP1+ Macs ex vivo
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S17 shows the spatial localization of macrophage subsets and T-cell populations in representative tumors
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Figure S17 shows the spatial localization of macrophage subsets and T-cell populations in representative tumors